ClinicalTrials.gg
CompletedNCT01244061Updated Jun 9, 2014Results posted

A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider

A Phase 4 interventional study of Varenicline and Placebo in Smoking Cessation, sponsored by Pfizer. Completed at 37 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-09.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
498
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
30th of 110
498 · median 209
Started
2010
with 6 others
Phase 4
47 of 110
3 open now
Registered
52nd of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 30th largest by enrollment, is one of 7 that started in 2010, is one of 47 in phase 4, and was the 52nd registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Smokers aged 18 years or above and wanting to stop smoking
  • Smokers who have smoked an average of at least 10 cigarettes per day over the last 4 weeks
  • Smokers who have tried before to stop smoking at least once with varenicline, and who took varenicline for at least 2 weeks
  • The last attempt to stop smoking must be at least 3 months before entering the study

Exclusion criteria

Exclusion Criteria:

  • Individuals who have not tolerated varenicline well previously, or who have a current or prior medical or psychiatric history that would make entry into the trial inadvisable
  • Individuals who have previously participated in clinical trials of varenicline
  • Individuals who have been participating in another smoking cessation trial within the last 3 months, or other drug trial within the last 30 days
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
498 participants (actual)

Study arms

  • Experimental
    Varenicline

    Drug: Varenicline

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Varenicline 1mg twice daily

  • DrugPlacebo

    Matched placebo twice daily

06

What researchers measure

Primary outcomes

  1. Continuous Abstinence Rate (CAR) From Week 9 Through Week 12

    The percentage of participants who, from Week 9 through Week 12, reported no smoking and no use of other nicotine-containing products since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have carbon monoxide (CO)\> 10ppm at any visits during this time frame.

    Time frame: Week 9 through Week 12

Secondary outcomes

  1. CAR From Week 9 Through Week 52

    The percentage of participants who, from Week 9 through Week 52, reported no smoking (Weeks 9 through 52) and no use of other nicotine-containing products (Weeks 9 through 12), or no use of other tobacco products (Weeks 13 through 52), since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have CO \>10 ppm at any of these visits during this time frame.

    Time frame: Week 9 through Week 52

  2. CAR From Week 9 Through Week 24

    The percentage of participants who, from Week 9 through Week 24, reported no smoking (Weeks 9 through 24) and no use of other nicotine-containing products (Weeks 9 through 12), or no use of other tobacco products (Weeks 13 through 24), since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have CO \>10 ppm at any of these visits during this time frame.

    Time frame: Week 9 through Week 24

  3. 7-day Point Prevalence (PP) of Abstinence at Weeks 12, 24, and 52

    The secondary endpoint of 7-day point prevalence of smoking cessation was determined by evaluating a participant's cigarette smoking status, and other nicotine (and/or other tobacco) use, based on the "last 7 days" questions in the Nicotine Use Inventory. Additionally, a participant was not considered a responder if the expired CO was \>10 ppm at the time point being summarized. Participants were considered responders independently at each visit.

    Time frame: Weeks 12, 24 and 52

07

Results

Posted Jun 9, 2014
Limitations and caveats
One SAE, exposure via semen, was not included under the Adverse Events since this event was considered to be experienced by a non-study participant, who was the study participant's partner. This event was coded as nonserious in the safety database.

Participant flow

This was a Phase 4, randomized, double-blind, placebo-controlled, parallel group, 2-arm, multicenter study. A total of 498 participants were randomized into the study at 36 investigator sites.

Participant flow — Overall Study
MilestoneVareniclinePlacebo
Started251247
Completed169144
Not completed82103
Withdrew: Death10
Withdrew: Did not meet entrance criteria10
Withdrew: Lack of efficacy13
Withdrew: Lost to follow-up3430
Withdrew: Withdrawal by subject2946
Withdrew: Other819
Withdrew: Protocol violation11
Withdrew: Adverse event52
Withdrew: Randomized but not treated22

Outcome measures

PrimaryContinuous Abstinence Rate (CAR) From Week 9 Through Week 12

The percentage of participants who, from Week 9 through Week 12, reported no smoking and no use of other nicotine-containing products since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have carbon monoxide (CO)\> 10ppm at any visits during this time frame.

Time frame:
Week 9 through Week 12
Reported as:
Number · Percentage of participants
Continuous Abstinence Rate (CAR) From Week 9 Through Week 12
Percentage of participantsVareniclinePlacebo
Continuous Abstinence Rate (CAR) From Week 9 Through Week 1245.011.8
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (The statistical significance was declared for each hypothesis firstly for CAR Weeks 9-12, and then secondly for CAR Weeks 9-52 until a p-value \> 0.05 was obtained, at which point the hypothesis would be declared to be not statistically significant.) · Odds ratio (or): 7.08 · 95% CI 4.34 to 11.55The analysis model included main effect of treatment and pooled center.
SecondaryCAR From Week 9 Through Week 52

The percentage of participants who, from Week 9 through Week 52, reported no smoking (Weeks 9 through 52) and no use of other nicotine-containing products (Weeks 9 through 12), or no use of other tobacco products (Weeks 13 through 52), since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have CO \>10 ppm at any of these visits during this time frame.

Time frame:
Week 9 through Week 52
Reported as:
Number · Percentage of participants
CAR From Week 9 Through Week 52
Percentage of participantsVareniclinePlacebo
CAR From Week 9 Through Week 5220.13.3
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (Statistical significance was declared for each hypothesis in the order above until a p-value \>0.05 was obtained, at which point the hypothesis was declared to be not statistically significant.) · Odds ratio (or): 9.00 · 95% CI 3.97 to 20.41The analysis model included main effect of treatment and pooled center.
SecondaryCAR From Week 9 Through Week 24

The percentage of participants who, from Week 9 through Week 24, reported no smoking (Weeks 9 through 24) and no use of other nicotine-containing products (Weeks 9 through 12), or no use of other tobacco products (Weeks 13 through 24), since the last study visit/last contact (on the Nicotine Use Inventory) and who did not have CO \>10 ppm at any of these visits during this time frame.

Time frame:
Week 9 through Week 24
Reported as:
Number · Percentage of participants
CAR From Week 9 Through Week 24
Percentage of participantsVareniclinePlacebo
CAR From Week 9 Through Week 2428.97.8
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (The statistical test was two-sided and at a 0.05 level of significance. No adjustment was made for the analysis of multiple secondary endpoints.) · Odds ratio (or): 5.83 · 95% CI 3.25 to 10.44The analysis model included main effect of treatment and pooled center.
Secondary7-day Point Prevalence (PP) of Abstinence at Weeks 12, 24, and 52

The secondary endpoint of 7-day point prevalence of smoking cessation was determined by evaluating a participant's cigarette smoking status, and other nicotine (and/or other tobacco) use, based on the "last 7 days" questions in the Nicotine Use Inventory. Additionally, a participant was not considered a responder if the expired CO was \>10 ppm at the time point being summarized. Participants were considered responders independently at each visit.

Time frame:
Weeks 12, 24 and 52
Reported as:
Number · Percentage of participants
7-day Point Prevalence (PP) of Abstinence at Weeks 12, 24, and 52
Percentage of participantsVareniclinePlacebo
Week 1253.014.7
Week 2432.915.5
Week 5228.912.2
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (The statistical test was two-sided and at a 0.05 level of significance. No adjustment was made for the analysis of multiple secondary endpoints.) · Odds ratio (or): 7.85 · 95% CI 4.92 to 12.51The analysis model included main effect of treatment and pooled center.
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (The statistical test was two-sided and at a 0.05 level of significance. No adjustment was made for the analysis of multiple secondary endpoints.) · Odds ratio (or): 2.94 · 95% CI 1.86 to 4.64The analysis model included main effect of treatment and pooled center.
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (The statistical test was two-sided and at a 0.05 level of significance. No adjustment was made for the analysis of multiple secondary endpoints.) · Odds ratio (or): 3.06 · 95% CI 1.88 to 4.97The analysis model included main effect of treatment and pooled center.

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline—7/249 (2.8%)145/249 (58.2%)
Placebo—4/245 (1.6%)70/245 (28.6%)
Most frequent serious events
Most frequent serious events
EventVareniclinePlacebo
Acute coronary syndromeCardiac disorders0/2491/245
HypersensitivityImmune system disorders1/2491/245
Ligament ruptureInjury, poisoning and procedural complications0/2491/245
HyperventilationRespiratory, thoracic and mediastinal disorders0/2491/245
Chest painGeneral disorders1/2490/245
Allergy to chemicalsImmune system disorders1/2490/245
PyelonephritisInfections and infestations1/2490/245
Ankle fractureInjury, poisoning and procedural complications1/2490/245
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/2490/245
Knee arthroplastySurgical and medical procedures1/2490/245
Most frequent other events
Most frequent other events
EventVareniclinePlacebo
NauseaGastrointestinal disorders66/24922/245
Abnormal dreamsPsychiatric disorders36/2490/245
HeadacheNervous system disorders26/24924/245
NasopharyngitisInfections and infestations19/24917/245
Upper respiratory tract infectionInfections and infestations19/24917/245
InsomniaPsychiatric disorders17/2490/245
DiarrhoeaGastrointestinal disorders15/2490/245
ConstipationGastrointestinal disorders13/2490/245
FatigueGeneral disorders13/2490/245
Sleep disorderPsychiatric disorders13/2490/245

Baseline characteristics

Age, Customized
Age, Customized(number of participants)VareniclinePlaceboTotal
< 18 years000
18-44 years9494188
45-64 years135139274
>= 65 years201232
Sex: Female, Male
Sex: Female, Male(Participants)VareniclinePlaceboTotal
Female125124249
Male124121245
08

Study locations

37 sites
  • Ronald Reagan University of California Los Angeles Medical Center
    Los Angeles, California 90095-6984, United States
  • University of California Los Angeles David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • The University of Maryland
    College Park, Maryland 20742, United States
  • The Center for Pharmaceutical Research, PC
    Kansas City, Missouri 64114, United States
  • Oregon Health and Science University
    Portland, Oregon 97239-3098, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • Australian Clinical Research Network
    Maroubra, New South Wales 2035, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • AusTrials Australia
    Sherwood, Queensland 4075, Australia
  • Emeritus Research
    Malvern, Victoria 3145, Australia
  • Universitair Ziekenhuis Antwerpen, Afdeling Pneumologie
    Edegem, 2650, Belgium
  • Universitaire Ziekenhuizen Leuven/Pneumologie
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liege
    Liege, 4000, Belgium
  • Cliniques Universitaires U.C.L. de Mont-Godinne/Laboratoire
    Yvoir, 5530, Belgium
  • Office of Dr. Ronald Collette
    Burnaby, British Columbia V5G 1T4, Canada
  • White Hills Medical Clinic
    St. John's, Newfoundland and Labrador A1A 3R5, Canada
  • Canadian Phase Onward Inc.
    Toronto, Ontario M3H 5S4, Canada
  • Clinique des maladies Lipidiques de Quebec
    Quebec, G1V 4M6, Canada
  • Fakultni nemocnice Brno
    Brno, 625 00, Czech Republic
  • Krajska nemocnice Liberec a.s., Plicni oddeleni
    Liberec 1, 460 01, Czech Republic
  • Mestska nemocnice Ostrava, Plicni oddeleni
    Ostrava 1, 728 80, Czech Republic
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 120 00, Czech Republic
  • CHU de la Cavale Blanche
    Brest, 29609, France
  • CHU Côte de Nacre, Unité de Coordination de Tabacologie
    Caen, 14033, France
  • Hopital Arnaud de Villeneuve
    Montpellier Cedex 5, 34295, France
  • Klinische Forschung Berlin
    Berlin, 10787, Germany
  • Universitaetsklinikum Goettingen Zentrum Innere Medizin Abteilung Kardiologie und Pneumologie
    Goettingen, 37075, Germany
  • Klinische Forschung Hamburg GmbH
    Hamburg, 20253, Germany
  • Ludwig Maximilians-Universitaet Muenchen
    Muenchen, 80336, Germany
  • FOCUS Clinical Drug Development GmbH
    Neuss, 41460, Germany
  • Synexus Thames Valley Clinical Research Centre
    Reading, Berks RG2 0TG, United Kingdom
  • Synexus Lancashire Clinical Research Centre
    Chorley, Lancashire PR7 7NA, United Kingdom
  • Synexus Scotland Clinical Research Centre
    Glasgow, G20 0SP, United Kingdom
  • Synexus, Merseyside Clinical Research Centre
    Liverpool, L22 0LG, United Kingdom
  • William Harvey Research Institute,
    London, EC1M 6BQ, United Kingdom
09

References and documents

Publications

  • Gonzales D, Hajek P, Pliamm L, Nackaerts K, Tseng LJ, McRae TD, Treadow J. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2014 Sep;96(3):390-6. doi: 10.1038/clpt.2014.124. Epub 2014 Jun 9. PubMed 24911368 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2010
First posted
Nov 19, 2010
Start
Dec 2010
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Jun 9, 2014
Last update
Jun 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01244061
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 19, 2010
Start date
Dec 2010
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Jun 9, 2014
Last update
Jun 9, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion